QTTB — Q32 Bio Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1661998 ·
Last close
$15.68
Market Cap
$465.83M
52W High
$23.57
52W Low
$4.97
ADV30
1,894,240
Next earnings
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -7,722,000 -7,609,000 63,675,000 50,751,000 17,362,000
Dec 2025 53,737,000 45,879,000 57,730,000 61,776,000 48,297,000 19,762,000
Sep 2025 0 -7,577,000 -7,389,000 57,784,000 49,039,000 76,232,000
Jun 2025 0 -9,171,000 -9,489,000 66,117,000 54,832,000 78,352,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-33,543,000
Investing CF
$7,000,000
Financing CF
$-3,125,000
CapEx
$-60,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-3.74
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-204,993,000
Inventory
Receivables
$5,392,000
ST Investments
EBIT TTM
$30,921,000
Pretax Income TTM
$29,821,000
Interest Exp TTM
$1,100,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$53,737,000
EBITDA
$21,770,000
Free Cash Flow
$9,871,000
Enterprise Value
$226,736,816
Total Cash
$50,751,000
Total Debt
$13,646,000
Shares Out
29,708,814
Trailing EPS
$2.78
Book Value
$3.17
ROE
157.2%
ROA
18.7%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 53,737,000 16,902,000 29,821,000 61,776,000 19,762,000 -33,543,000
Dec 2024 0 -66,102,000 -47,733,000 92,332,000 86,657,000 -67,715,000
Dec 2023 -6,651,000 -48,255,000 -53,743,000 47,057,000 229,978,000 -18,677,000
Dec 2022 6,651,000 -39,225,000 -42,809,000 61,774,000 192,486,000 -10,957,000
Dec 2021

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.42

Peers — same industry

TickerNameMarket CapLastDaily %
VREOF Vireo Growth Inc. $466.74M $9.49
AQST Aquestive Therapeutics, Inc. $463.60M $3.69
RZLT Rezolute, Inc. $454.50M $4.72
HELP CYBIN INC. $484.72M $7.82
SLN Silence Therapeutics plc $495.49M $10.49

News headlines (Yahoo Finance, 1h cache)

Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice
2026-07-20 16:00 · Yahoo
Wall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
2026-07-15 13:55 · Yahoo
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
2026-07-15 02:58 · Yahoo
Q32 Bio stock surges 83% on positive alopecia drug trial data
2026-07-14 13:04 · Yahoo
Q32 Bio (QTTB) After Positive Trial Data Is It A Buy Or Already Fairly Valued
2026-07-14 10:14 · Yahoo
Why Did AAPL, QTTB, CSX Stocks Surge To 52-Week Highs Today?
2026-07-14 02:14 · Yahoo
Why Q32 Bio Stock Skyrocketed Today
2026-07-14 01:58 · Yahoo
QTTB Stock Clocks Best Day In A Year Following Positive Alopecia Data — Analyst Sees Further 200% Upside
2026-07-13 21:00 · Yahoo
Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-07-13 20:01 · Yahoo
Top Midday Gainers
2026-07-13 17:38 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.